FREE Account Opening + No Clearing Fees

Krishna Institute (KIMS) IPO review (May apply)

Review By Dilip Davda on June 12, 2021

•    KIMS is one of the largest corporate healthcare group in the southern region.
•    The issue consists of 90% OFS portion.
•    The company has posted growth in its top and bottom lines for the last three fiscals.
•    Based on P/E and P/BV parameters, the issue is fully priced.
•    Investment with a long term perspective may be considered.

After mega IPO of Sona BLW with approx. 94% OFS (Offer for sale) portion, we have yet another IPO where the OFS portion is a little over 90%. Both these issues had only a 10% quota for retail investors. For both these IPOs, QIBs and HNIs will have a masterstroke, opines observers. As per market sources, NBFCs are competing to lure HNIs with lower interest rate funding options, and thus it would be interesting to see the final tally for these two IPOs in particular and the other IPOs in general.

Krishna Institute of Medical Sciences Ltd.  (KIMS) is one of the largest corporate healthcare groups in AP and Telangana in terms of the number of patients treated and treatments offered, according to the CRISIL Report commissioned by it. KIMS provides multi-disciplinary integrated healthcare services, with a focus on primary secondary & tertiary care in Tier 2-3 cities and primary, secondary, tertiary and quaternary healthcare in Tier 1 cities.

The company operates 9 multi-speciality hospitals under the 'KIMS Hospitals' brand, with an aggregate bed capacity of 3,064, including over 2,500 operational beds as of March 31, 2021, which is 2.2 times more beds than the second-largest provider in AP and Telangana, according to the CRISIL Report commissioned by it. The company offers a comprehensive range of healthcare services across over 25 specialities and super specialities, including cardiac sciences, oncology, neurosciences, gastric sciences, orthopaedics, organ transplantation, renal sciences and mother & child care.

It has grown from a single hospital to a chain of multi-speciality hospitals through organic growth and strategic acquisitions. Its first hospital in the network was established in Nellore (AP) in 2000 and has a capacity of approximately 200 beds. The company's flagship hospital at Secunderabad (Telangana) is one of the largest private hospitals in India at a single location (excluding medical colleges), according to the CRISIL Report commissioned by it, with a capacity of 1,000 beds as of March 31, 2021. It has significantly expanded its hospital network in recent years through acquisitions of hospitals in Ongole (AP) in Fiscal Year 2017, Vizag (AP) and Anantapur (AP) in the Fiscal Year 2019 and Kurnool (AP) in Fiscal Year 2020.

Approximately one-third of its 3,064 beds were launched in the last four years. It has added over 940 beds, in aggregate, in its hospitals in Visakhapatnam (Vizag) (AP), Anantapur (AP), Rajamundry (AP) and Kurnool (AP) in Fiscal Years 2019 and 2021, and improved the overall bed occupancy rate in these hospitals from 71.83% to 78.60% in the same period.

It strategically focuses on the southern Indian healthcare market where it has a strong understanding of regional nuances, customer culture and the mindset of medical professionals and where there is a significant and growing need for quality and affordable healthcare services. Each of its hospitals also has integrated diagnostic services and pharmacies that cater to patients.

To part finance its plans for repayment-pre-payment of certain borrowing in full or part (Rs. 150.00 cr.) and general corpus fund, KIMS is coming out with a maiden book built IPO having fresh equity issue worth Rs. 200 cr. (approx. 2424240 equity shares) and an offer for sale of 23560538 equity shares (Rs. 1943.74 cr.) of Rs. 10 each to mobilize Rs. 2143.74 cr. (at the upper price band).  It has fixed the price band of Rs. 815 - Rs. 825 /825 and minimum application is to be made for 18 shares and in multiples thereon, thereafter. The issue opens for subscription on June 16, 2021, and will close on June 18, 2021. Post allotment, shares will be listed on BSE and NSE. The issue constitutes 32.47% of the post issue paid-up capital of the company.

The company has reserved a portion worth Rs. 20 cr. for its eligible employees and offering a discount of Rs. 40 per share to them. From the residual part, the company has allocated 75% for QIBs, 15% for HNIs and 10% for retail investors.

Book Running Lead Managers to this issue are Kotak Mahindra Capital Co. Ltd., Axis Capital Ltd., Credit Suisse Securities (India) Pvt. Ltd. and IIFL Securities Ltd., while Link Intime India Pvt. Ltd. is the registrar to the issue.

Having issued initial equity at par, the company raised further equity in the price range of Rs. 95 to Rs. 1434.72 per share between March 2004 and February 2021. It has also issued bonus shares in the ratio of 1 for 4 in February 2009, 1 for 10 in October 2013, 1 for 2 in January 2015, 1 for 1 in August 2015 and 3 for 1 in January 2016.

The average cost of acquisition of shares by the promoters is Rs. 30.43, Rs. 89.85, Rs. 95.40, Rs. 114.94 and Rs. 121.97 per share and selling stakeholders is ranging from Rs. 5.15 to Rs. 310.26 per share (refer to page 26 and 27 of the offer document).

Post issue, KIMS's current paid-up equity capital of Rs. 77.59 cr. will stand enhanced to Rs. 80.02 cr. Based on the upper cap of the issue price, the company is looking for a market cap of Rs. 6601.45 cr.

On the financial performance front, for the last three fiscals, KIMS has (on a consolidated basis), posted turnover/net profit (loss) of Rs. 923.87 cr. / Rs. - (48.81) cr. (FY19), Rs. 1128.73 cr. / Rs. 115.07 cr. (FY20) and Rs. 1340.10 cr. / Rs. 205.48 cr. (FY21). Thus it has posted a growing pattern in its top as well as bottom lines for all these years.

For the last three fiscals, the company has, on a consolidated basis, posted an average EPS of Rs. 17.35 and an average RoNW of 16.82%. The issue is priced at a P/BV of 7.15 based on its NAV of Rs. 115.36 as of March 31, 2021, and at a P/BV of 6.21 based on its post-issue NAV of Rs. 132.92 (at the upper price band).

If we attribute FY21 earnings on post-issue fully diluted equity, then the asking price is at a P/E of around 32.13. The issue is fully priced in terms of P/E in comparison with listed peers that are trading at a negative P/E.

As per offer documents, KIMS has not paid any dividend in the last three fiscals but will follow a prudent dividend policy based on its financial performance, future prospects and the procedure framed for the same. (refer to page 232 of the offer document).

As per the RHP data, KIMS has shown Apollo Hospital, Fortis Healthcare, Narayan Hrudayalaya and Max Healthcare as its listed peers. They are currently trading at a P/E of around 00, 00, 00 and 00 (as of June 11, 2021). However, they are not truly comparable on an apple to apple basis. As all these listed peers have posted negative earnings, they are indicating 00 P/E but still finds fancy from investors across the board.

The four BRLMs associated with the offer have handled 29 public offers in the past three years out of which 10 offers closed below the offer price on the listing date.

Conclusion / Investment Strategy

We are witnessing fancy for health care segment following global pandemic and the likely trends of changing lifestyle with health consciousness and spending for the same. This company has ultra-modern equipment and has been posting growth in its top and bottom lines. Investors may consider long term investment in this fully priced offer.

Review By Dilip Davda on June 12, 2021

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. My reviews do not cover GMP market and operators game plans. Any reader taking decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in stock markets is subject to unpredictable market-related risks. The above information is based on RHP and other documents available as of date coupled with market perception. The author has no plans to invest in this offer.

About Dilip Davda

Dilip Davda, a freelance journalist

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

(Dilip Davda -SEBI registered Research Analyst-Mumbai,

Registration no. INH000003127 (Perpetual)

Email id: ).


  1. 1. Why KIMS IPO?

    The initial public offer (IPO) of Krishna Institute of Medical Sciences Limited offers an early investment opportunity in Krishna Institute of Medical Sciences Limited. A stock market investor can buy KIMS IPO shares by applying in IPO before Krishna Institute of Medical Sciences Limited shares get listed at the stock exchanges. An investor could invest in KIMS IPO for short term listing gain or a long term.

  2. 3. KIMS IPO what should investors do?

    KIMS IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the KIMS IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.

  3. 4. Is KIMS IPO good?

    Our recommendation for KIMS IPO is to subscribe for long term.

  4. 5. Is KIMS IPO worth Investing?

    As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to subscribe for long term to the KIMS IPO.

  5. 6. When will KIMS IPO allotment status?

    The KIMS IPO allotment status will be available on or around June 23, 2021. The allotted shares will be credited in demat account by June 25, 2021. Visit KIMS IPO allotment status to check.

  6. 7. When will KIMS IPO list?

    The KIMS IPO will list on Monday, June 28, 2021, at BSE, NSE.